|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016141230A1
(en)
|
2015-03-05 |
2016-09-09 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
|
KR102847350B1
(ko)
|
2015-11-25 |
2025-08-19 |
주식회사 리가켐바이오사이언스 |
분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
|
|
AU2016359234B2
(en)
|
2015-11-25 |
2022-09-08 |
Ligachem Biosciences Inc. |
Conjugates comprising peptide groups and methods related thereto
|
|
HRP20240795T1
(hr)
|
2015-11-25 |
2024-09-13 |
Ligachem Biosciences Inc. |
Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
|
|
US10913780B2
(en)
|
2016-03-24 |
2021-02-09 |
The Administrators Of The Tulane Educational Fund |
Conjugates, their compositions, their uses, and their methods of making
|
|
KR20180134351A
(ko)
*
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
MX2019001302A
(es)
*
|
2016-08-09 |
2019-06-12 |
Seattle Genetics Inc |
Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
|
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
|
TWI835714B
(zh)
|
2016-10-18 |
2024-03-21 |
美商思進公司 |
菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
|
|
KR20240000650A
(ko)
|
2016-10-19 |
2024-01-02 |
인벤라 인코포레이티드 |
항체 구조물
|
|
FR3060567B1
(fr)
*
|
2016-12-19 |
2019-05-24 |
Ecole Normale Superieure De Lyon |
Substrat de glycosidase fluorogene et procede de detection associe
|
|
EP3559039A1
(en)
|
2016-12-22 |
2019-10-30 |
Università Degli Studi Magna Graecia Catanzaro |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
|
WO2018124758A2
(ko)
*
|
2016-12-28 |
2018-07-05 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
KR20250171447A
(ko)
|
2017-02-28 |
2025-12-08 |
이뮤노젠 아이엔씨 |
자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
|
|
EP4011396A1
(en)
*
|
2017-03-10 |
2022-06-15 |
QuiaPEG Pharmaceuticals AB |
Releasable conjugates
|
|
AU2018237683A1
(en)
*
|
2017-03-24 |
2019-10-31 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
MX2019011655A
(es)
|
2017-03-29 |
2019-12-19 |
Legochem Biosciences Inc |
Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
|
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
CA3061907A1
(en)
*
|
2017-05-02 |
2018-11-08 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
|
WO2019051489A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
WO2019051488A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
IL301637B2
(en)
|
2017-09-29 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
CA3079215A1
(en)
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cd117+ cells
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
WO2019108863A1
(en)
|
2017-11-29 |
2019-06-06 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cd5+ cells
|
|
WO2019118884A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
EP3728280B1
(en)
*
|
2017-12-21 |
2023-06-28 |
Pharmacytics B.V. |
Method for improving the oral bioavailability of a drug
|
|
KR20200121800A
(ko)
|
2018-01-05 |
2020-10-26 |
싸이브렉사 1, 인크. |
산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
|
|
TW202003044A
(zh)
*
|
2018-03-09 |
2020-01-16 |
瑞典商奎亞培格製藥公司 |
可釋放之抗體結合物
|
|
CA3094313A1
(en)
*
|
2018-04-06 |
2019-10-10 |
Seattle Genetics, Inc. |
Camptothecin peptide conjugates
|
|
IL300091A
(en)
|
2018-05-01 |
2023-03-01 |
Revolution Medicines Inc |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
|
CN112368289B
(zh)
|
2018-05-01 |
2024-02-20 |
锐新医药公司 |
作为mtor抑制剂的c26-连接的雷帕霉素类似物
|
|
JP7459063B2
(ja)
|
2018-05-09 |
2024-04-01 |
レゴケム バイオサイエンシズ， インク． |
抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法
|
|
WO2019222272A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2019234136A1
(en)
|
2018-06-05 |
2019-12-12 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
|
TWI851577B
(zh)
*
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
|
AU2019337654A1
(en)
|
2018-09-12 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
AU2019340472A1
(en)
*
|
2018-09-12 |
2021-04-01 |
Quiapeg Pharmaceuticals Ab |
Releasable GLP-1 conjugates
|
|
MA53765B2
(fr)
|
2018-12-21 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Tubulysines et conjugués tubulysines-protéines
|
|
SG11202110287QA
(en)
|
2019-04-24 |
2021-10-28 |
Heidelberg Pharma Res Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
TW202116356A
(zh)
|
2019-07-10 |
2021-05-01 |
美商斯布雷克薩三號公司 |
作為治療劑之微管靶向藥劑之肽結合物
|
|
CN114341162B
(zh)
|
2019-07-10 |
2025-10-17 |
赛博克萨2公司 |
作为治疗剂的细胞毒素的肽缀合物
|
|
WO2021030665A1
(en)
|
2019-08-15 |
2021-02-18 |
Silverback Therapeutics, Inc. |
Formulations of benzazepine conjugates and uses thereof
|
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
AU2020356955A1
(en)
*
|
2019-10-04 |
2022-04-14 |
Seagen Inc. |
Camptothecin peptide conjugates
|
|
WO2021072203A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
|
|
WO2021072330A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
|
|
WO2021092287A1
(en)
|
2019-11-08 |
2021-05-14 |
North Carolina State University |
Cross-linking compounds and methods of use thereof
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110974975B
(zh)
*
|
2019-12-12 |
2023-10-20 |
成都百利多特生物药业有限责任公司 |
一种快速释放的抗体药物偶联物
|
|
CN114569735A
(zh)
*
|
2020-12-01 |
2022-06-03 |
泰州复旦张江药业有限公司 |
一种连接基-药物偶联物、制备方法及应用
|
|
EP4257153B1
(en)
*
|
2020-12-04 |
2025-11-12 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
|
|
KR20230121842A
(ko)
*
|
2020-12-18 |
2023-08-21 |
상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 |
Trop2를 표적으로 하는 항체 약물 접합체, 이의 제조방법 및 용도
|
|
EP4265274B1
(en)
*
|
2020-12-18 |
2025-03-19 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
|
|
MX2023007126A
(es)
|
2020-12-23 |
2023-09-04 |
Univ Muenchen Ludwig Maximilians |
Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos.
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
AU2022253474A1
(en)
|
2021-04-08 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
JP7717832B2
(ja)
|
2021-04-10 |
2025-08-04 |
ジェンマブ エー／エス |
Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
|
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
US12006314B2
(en)
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
TW202320858A
(zh)
|
2021-07-19 |
2023-06-01 |
美商薩諾管理公司 |
免疫接合物及方法
|
|
US11806405B1
(en)
|
2021-07-19 |
2023-11-07 |
Zeno Management, Inc. |
Immunoconjugates and methods
|
|
MX2024002571A
(es)
|
2021-09-03 |
2024-03-20 |
Toray Industries |
Composicion farmaceutica para tratamiento y/o prevencion de cancer.
|
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
EP4460330A1
(en)
*
|
2022-01-06 |
2024-11-13 |
Virtuoso Binco, Inc. |
Conjugates, compositions and methods of use
|
|
AU2023251200A1
(en)
|
2022-04-07 |
2024-10-03 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
|
AU2023275778A1
(en)
|
2022-05-25 |
2024-12-12 |
Revolution Medicines, Inc. |
Methods of treating cancer with an mtor inhibitor
|
|
KR20250031149A
(ko)
|
2022-06-30 |
2025-03-06 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
WO2024025396A1
(ko)
*
|
2022-07-28 |
2024-02-01 |
주식회사 레고켐 바이오사이언스 |
신규 오리스타틴 전구약물
|
|
JP2025530213A
(ja)
|
2022-09-09 |
2025-09-11 |
ミリックス ファーマ リミテッド |
Ｎｍｔ阻害剤を含む抗体薬物コンジュゲート及びその使用
|
|
TWI903241B
(zh)
*
|
2022-09-30 |
2025-11-01 |
美商西雅圖免疫公司 |
一種帶有高穩定性親水連接單元的奧瑞他汀類藥物及其偶聯物
|
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
|
CN120936385A
(zh)
|
2023-03-13 |
2025-11-11 |
海德堡医药研究有限责任公司 |
用于在癌症治疗中使用的皮下施用的抗体-药物缀合物
|
|
KR20240159447A
(ko)
|
2023-04-28 |
2024-11-05 |
주식회사 에이비켐바이오 |
말레이미드 함유 링커-페이로드 접합체
|
|
KR20240159448A
(ko)
|
2023-04-28 |
2024-11-05 |
주식회사 에이비켐바이오 |
균일한 dar를 갖는 신규한 항체-약물 중합체의 제조방법
|
|
KR20250074353A
(ko)
|
2023-11-20 |
2025-05-27 |
주식회사 에이비켐바이오 |
높은 dar를 갖는 신규한 항체-약물 중합체, 이의 제조방법 및 이의 용도
|
|
EP4543314A1
(en)
*
|
2023-06-22 |
2025-04-30 |
Cilag GmbH International |
Systems and methods for embedding medical additives into bioabsorbable materials
|
|
US20240423619A1
(en)
|
2023-06-22 |
2024-12-26 |
Cilag Gmbh International |
Surgical adjuncts including fluid barriers
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
CN119424671A
(zh)
*
|
2023-08-01 |
2025-02-14 |
上海新理念生物医药科技有限公司 |
含糖基吡啶型连接子的抗体药物偶联物
|
|
AU2024339683A1
(en)
|
2023-09-13 |
2026-03-26 |
Toray Industries, Inc. |
Pharmaceutical composition for treating, preventing and/or diagnosing cancer
|
|
AU2024353316A1
(en)
|
2023-09-26 |
2026-03-26 |
Genmab A/S |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2026039642A1
(en)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Anti-mesothelin antibody conjugates and methods of use thereof
|